Bio-Path Holdings Company Profile (NASDAQ:BPTH)

About Bio-Path Holdings

Bio-Path Holdings logoBio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification. Its lead drug candidate, Liposomal Grb2 (BP1001), targets the protein Growth factor receptor-bound protein 2 (Grb2). Its other liposome delivered antisense drug candidate, Liposomal Bcl2 (BP1002), targets the protein B-cell lymphoma 2 (Bcl2). BP1001 is in Phase II clinical trials for acute myeloid leukemia, and for blast phase and accelerated phase chronic myelogenous leukemia. BP1002 is intended to target the lymphoma and certain solid tumor markets. BP1001 is also in preclinical studies for solid tumors, including triple negative breast cancer and inflammatory breast cancer.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Delivery
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: BPTH
  • CUSIP:
Key Metrics:
  • Previous Close: $0.95
  • 50 Day Moving Average: $1.0012
  • 200 Day Moving Average: $1.2640
  • 52-Week Range: $95,645,000.00 - $0.81
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.62
  • P/E Growth: 0.0000
  • Market Cap: $90.66M
  • Outstanding Shares: 95,645,000
  • Beta: 2.64
Profitability:
  • Return on Equity: -81.94%
  • Return on Assets: -68.25%
Debt:
  • Current Ratio: 14.42%
  • Quick Ratio: 14.42%
Additional Links:
Companies Related to Bio-Path Holdings:

Analyst Ratings

Consensus Ratings for Bio-Path Holdings (NASDAQ:BPTH) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $3.50 (269.24% upside)

Analysts' Ratings History for Bio-Path Holdings (NASDAQ:BPTH)
Show:
DateFirmActionRatingPrice TargetDetails
11/12/2016Maxim GroupSet Price TargetBuy$2.00View Rating Details
8/11/2016Rodman & RenshawSet Price TargetBuy$5.00View Rating Details
(Data available from 2/19/2015 forward)

Earnings

Earnings History for Bio-Path Holdings (NASDAQ:BPTH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/14/2017        
11/10/2016Q316($0.02)($0.02)$2.50 millionViewListenView Earnings Details
5/11/2016Q1($0.01)($0.02)$2.33 millionViewListenView Earnings Details
3/15/2016Q4($0.01)($0.02)ViewN/AView Earnings Details
3/17/2015$0.01($0.02)ViewN/AView Earnings Details
11/18/2014($0.01)($0.01)ViewN/AView Earnings Details
8/18/2014Q214($0.01)($0.01)ViewN/AView Earnings Details
4/2/2014$0.01$0.01ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Bio-Path Holdings (NASDAQ:BPTH)
Current Year EPS Consensus Estimate: $-0.0900 EPS
Next Year EPS Consensus Estimate: $-0.1100 EPS

Dividends

Dividend History for Bio-Path Holdings (NASDAQ:BPTH)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Bio-Path Holdings (NASDAQ:BPTH)
Insider Ownership Percentage: 12.54%
Institutional Ownership Percentage: 21.00%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/13/2015Michael J GarrisonDirectorBuy7,343$1.22$8,958.46View SEC Filing  
7/9/2015Michael J GarrisonDirectorBuy8,724$1.17$10,207.08View SEC Filing  
7/8/2015Michael J GarrisonDirectorBuy60,000$1.19$71,400.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Bio-Path Holdings (NASDAQ:BPTH)
DateHeadline
News IconStock Watch for Biopath Holdings Inc (BPTH) - Davidson Register (NASDAQ:BPTH)
davidsonregister.com - February 10 at 3:32 PM
globenewswire.com logoBio-Path Holdings to Present at the 19th Annual BIO CEO & Investor Conference - GlobeNewswire (press release) (NASDAQ:BPTH)
globenewswire.com - February 9 at 9:14 PM
marketexclusive.com logoBIO-PATH HOLDINGS, INC. (NASDAQ:BPTH) Files An 8-K Regulation FD Disclosure - Market Exclusive (NASDAQ:BPTH)
marketexclusive.com - February 9 at 9:14 PM
News IconEquity Rundown: RSI and CCI Check on Biopath Holdings Inc (BPTH) - Sherwood Daily (NASDAQ:BPTH)
sherwooddaily.com - February 3 at 9:12 PM
News IconIs this Stock Under $5 a Bargain: Bio-Path Holdings, Inc. (NASDAQ:BPTH) - Prospect Journal (NASDAQ:BPTH)
prospectjournal.com - February 1 at 9:16 PM
News IconNear-Term, Can This Stock Move the Needle: Bio-Path Holdings, Inc. (NASDAQ:BPTH) - Prospect Journal (NASDAQ:BPTH)
prospectjournal.com - January 31 at 2:24 AM
News IconRelative Strength Index Review on Shares of Biopath Holdings Inc (BPTH) - Sherwood Daily (NASDAQ:BPTH)
sherwooddaily.com - January 30 at 3:58 PM
News IconAverage Directional Index Review for Biopath Holdings Inc (BPTH) - Sherwood Daily (NASDAQ:BPTH)
sherwooddaily.com - January 27 at 4:59 PM
News IconRisky Play or Bargain? Update on Bio-Path Holdings, Inc. (NASDAQ:BPTH) - Prospect Journal (NASDAQ:BPTH)
prospectjournal.com - January 26 at 9:44 PM
News IconWilliams %R, RSI, and ADX Update for Biopath Holdings Inc (BPTH) - Sherwood Daily (NASDAQ:BPTH)
sherwooddaily.com - January 26 at 4:43 PM
News IconInvestors are Looking at Levels for Biopath Holdings Inc (BPTH) - Sherwood Daily (NASDAQ:BPTH)
sherwooddaily.com - January 25 at 5:00 PM
News IconTechnical Toolbox: Investor Focus on Biopath Holdings Inc (BPTH) - Sherwood Daily (NASDAQ:BPTH)
sherwooddaily.com - January 24 at 4:34 PM
News IconRSI Review on Shares of Biopath Holdings Inc (BPTH) - Sherwood Daily (NASDAQ:BPTH)
sherwooddaily.com - January 21 at 3:07 AM
News IconWhat are the Levels Indicating for This Stock: Biopath Holdings Inc (BPTH) - Sherwood Daily (NASDAQ:BPTH)
sherwooddaily.com - January 19 at 5:05 PM
News IconCan This Stock Price Climb The Ladder: Bio-Path Holdings, Inc. (NASDAQ:BPTH) - Prospect Journal (NASDAQ:BPTH)
prospectjournal.com - January 19 at 5:05 PM
News IconTrading Roundup: Checking Technicals for Biopath Holdings Inc (BPTH) - Sherwood Daily (NASDAQ:BPTH)
sherwooddaily.com - January 17 at 9:49 PM
News IconInvestors Priming the Pump as Stock Reaches Most Volatile List: Bio-Path Holdings, Inc. (NASDAQ:BPTH) - Wall Street Beacon (NASDAQ:BPTH)
wsbeacon.com - January 17 at 9:49 PM
News IconUpside Alert: Delving into Shares of Bio-Path Holdings, Inc. (NASDAQ:BPTH) - Prospect Journal (NASDAQ:BPTH)
prospectjournal.com - January 16 at 9:04 PM
News IconIs This Equity Ready for a Breakout: Bio-Path Holdings, Inc ... - Prospect Journal (NASDAQ:BPTH)
prospectjournal.com - January 6 at 2:29 AM
News IconPlacing This Stock in the Hotbed: Bio-Path Holdings, Inc. (NASDAQ:BPTH) - Prospect Journal (NASDAQ:BPTH)
prospectjournal.com - January 3 at 5:21 PM
News IconKeen Investors Taking a Look at Bio-Path Holdings, Inc. (NASDAQ:BPTH) - Prospect Journal (NASDAQ:BPTH)
prospectjournal.com - December 20 at 4:28 PM
News IconTop Stock With Upside & Growth Potential: Bio-Path Holdings, Inc. (NASDAQ:BPTH) - Prospect Journal (NASDAQ:BPTH)
prospectjournal.com - December 20 at 5:14 AM
biz.yahoo.com logoBIO-PATH HOLDINGS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosu (NASDAQ:BPTH)
biz.yahoo.com - December 16 at 4:21 PM
insidermonkey.com logoHow Noodles & Co (NDLS) Stacks Up Against Its Peers (NASDAQ:BPTH)
www.insidermonkey.com - December 15 at 9:27 PM
streetinsider.com logoBio-Path Holdings (BPTH) Announces Presentation of BP1001 Data as CML Treatment at ASH 2016 (NASDAQ:BPTH)
www.streetinsider.com - December 7 at 2:22 AM
us.rd.yahoo.com logoBio-Path Holdings Presents Clinical Data Evaluating BP1001 as a Treatment for Chronic Myelogenous Leukemia at the 58th Annual American Society of Hematology Annual Meeting (NASDAQ:BPTH)
us.rd.yahoo.com - December 6 at 4:18 PM
us.rd.yahoo.com logo7:01 am Bio-Path reviews BP1001 data as a treatment for chronic myelogenous leukemia at ASH 2016; results demonstrate BP1001 decreased the proliferation of Gleevec (imatinib)-resistant CML cells in a dose-dependent manner (NASDAQ:BPTH)
us.rd.yahoo.com - December 6 at 4:18 PM
biz.yahoo.com logoBIO-PATH HOLDINGS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:BPTH)
biz.yahoo.com - December 6 at 4:18 PM
News IconReady for an Upsurge? Analysts Chime in on Bio-Path Holdings, Inc. (NASDAQ:BPTH) - Prospect Journal (NASDAQ:BPTH)
prospectjournal.com - December 6 at 12:14 PM
streetinsider.com logoBio-Path Holdings (BPTH) Announces Presentation of BP1001 Data as CML Treatment at ASH 2016 - StreetInsider.com (NASDAQ:BPTH)
www.streetinsider.com - December 6 at 12:14 PM
capitalcube.com logoBio-Path Holdings, Inc. :BPTH-US: Earnings Analysis: Q3, 2016 By the Numbers : December 1, 2016 (NASDAQ:BPTH)
www.capitalcube.com - December 1 at 4:03 PM
News IconTraders are Keeping Track of Technicals on Shares of Biopath Holdings Inc (BPTH) - MicroCap Wired (NASDAQ:BPTH)
www.microcapwired.com - November 25 at 3:58 PM
News IconStock Review: ADX, MA, RSI Numbers in View for Biopath Holdings Inc (BPTH) - MicroCap Wired (NASDAQ:BPTH)
www.microcapwired.com - November 25 at 9:13 AM
News IconPenny Stock Spotlight: Focusing on Bio-Path Holdings, Inc. (NASDAQ:BPTH) - Duncan Research (NASDAQ:BPTH)
www.duncanindependent.com - November 23 at 9:59 PM
News IconChecking on Indicators for Biopath Holdings Inc (BPTH) - MicroCap Wired (NASDAQ:BPTH)
www.microcapwired.com - November 23 at 12:54 PM
News IconPenny Stock Making Waves: Investors Keen on Bio-Path Holdings, Inc. (NASDAQ:BPTH) - Duncan Research (NASDAQ:BPTH)
www.duncanindependent.com - November 22 at 11:31 AM
News IconWonder Stock Alert: Investors Curious About Bio-Path Holdings, Inc. (NASDAQ:BPTH) - Duncan Research (NASDAQ:BPTH)
www.duncanindependent.com - November 22 at 11:31 AM
News IconPenny Stock Focus: Narrowing the Lens On Bio-Path Holdings, Inc. (NASDAQ:BPTH) - Duncan Research (NASDAQ:BPTH)
www.duncanindependent.com - November 18 at 3:53 PM
News IconPenny Stock Making Waves: Taking a Second Look at Bio-Path Holdings, Inc. (NASDAQ:BPTH) - Duncan Research (NASDAQ:BPTH)
www.duncanindependent.com - November 17 at 8:50 PM
News IconTracking Technical Levels on Shares of Biopath Holdings Inc (BPTH) - MicroCap Wired (NASDAQ:BPTH)
www.microcapwired.com - November 17 at 8:50 PM
finance.yahoo.com logoBIO-PATH HOLDINGS INC Financials (NASDAQ:BPTH)
finance.yahoo.com - November 17 at 1:51 PM
News IconPenny Stock Making News: Putting the Microscope On Bio-Path Holdings, Inc. (NASDAQ:BPTH) - Duncan Research (NASDAQ:BPTH)
www.duncanindependent.com - November 15 at 4:09 PM
News IconThe Next Wonder Penny Stock? Investors Keen On Bio-Path Holdings, Inc. (NASDAQ:BPTH) - Duncan Research (NASDAQ:BPTH)
www.duncanindependent.com - November 15 at 4:09 PM
News IconPenny Stock News: Looking Closer At Bio-Path Holdings, Inc. (NASDAQ:BPTH) - Duncan Research (NASDAQ:BPTH)
www.duncanindependent.com - November 11 at 8:34 PM
einnews.com logoBio-Path Holdings Reports Third Quarter 2016 Financial Results (NASDAQ:BPTH)
it.einnews.com - November 11 at 1:21 PM
News IconTechnical Trading: Focus on Shares of Biopath Holdings Inc (BPTH) - MicroCap Wired (NASDAQ:BPTH)
www.microcapwired.com - November 10 at 3:20 PM
News IconPenny Stock Interest: Checking In On Bio-Path Holdings, Inc. (NASDAQ:BPTH) - Duncan Research (NASDAQ:BPTH)
www.duncanindependent.com - November 10 at 12:20 PM
biz.yahoo.com logoBIO-PATH HOLDINGS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh (NASDAQ:BPTH)
biz.yahoo.com - November 10 at 12:20 PM
biz.yahoo.com logoBIO-PATH HOLDINGS INC Files SEC form 10-Q, Quarterly Report (NASDAQ:BPTH)
biz.yahoo.com - November 9 at 10:33 PM
News IconPenny Stock Update: Traders Looking Closely at Bio-Path Holdings, Inc. (NASDAQ:BPTH) - Duncan Research (NASDAQ:BPTH)
www.duncanindependent.com - November 8 at 2:43 PM

Social

What is Bio-Path Holdings' stock symbol?

Bio-Path Holdings trades on the NASDAQ under the ticker symbol "BPTH."

Where is Bio-Path Holdings' stock going? Where will Bio-Path Holdings' stock price be in 2017?

2 equities research analysts have issued 12 month price objectives for Bio-Path Holdings' shares. Their predictions range from $2.00 to $5.00. On average, they expect Bio-Path Holdings' share price to reach $3.50 in the next year.

When will Bio-Path Holdings announce their earnings?

Bio-Path Holdings is scheduled to release their next quarterly earnings announcement on Tuesday, March, 14th 2017.

What are analysts saying about Bio-Path Holdings stock?

Here are some recent quotes from research analysts about Bio-Path Holdings stock:

  • According to Zacks Investment Research, "BIO-PATH is developing leading-edge, patented, liposomal drug delivery systems, with two clinical cancer drug candidates ready for the clinic and a third siRNA cancer drug undergoing final pre-clinical development. Bio-Path's drug delivery technology distributes nucleic acid drugs systemically, throughout the human body, via simple intravenous infusion. The delivery technology can be applied both to double stranded and single stranded nucleic acid compounds with the potential to revolutionize the treatment of cancer and other diseases where drugable targets of disease are well characterized. " (1/11/2017)

  • Maxim Group analysts commented, "Bio-Path presented BP1001 (Liposomal Grb2 Antisense) data as a poster presentation titled Phase I Study of BP1001 (Liposomal Grb2 Antisense) in Patients with Hematologic Malignancies" at ASCO. The data included results from the Phase I study of BP1001 for the treatment of acute myeloid leukemia (AML) and chronic myeloid leukemia (CML), and safety data from the Phase II study of BP1001 in combination with low-dose cytarabine (LDAC) for advanced AML. The poster was presented by Dr." (6/6/2016)

Who owns Bio-Path Holdings stock?

Bio-Path Holdings' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include State Street Corp (1.13%) and Raymond James Financial Services Advisors Inc. (0.81%).

Who sold Bio-Path Holdings stock? Who is selling Bio-Path Holdings stock?

Bio-Path Holdings' stock was sold by a variety of institutional investors in the last quarter, including Raymond James Financial Services Advisors Inc..

Who bought Bio-Path Holdings stock? Who is buying Bio-Path Holdings stock?

Bio-Path Holdings' stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp.

How do I buy Bio-Path Holdings stock?

Shares of Bio-Path Holdings can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Bio-Path Holdings stock cost?

One share of Bio-Path Holdings stock can currently be purchased for approximately $0.95.

Bio-Path Holdings (NASDAQ:BPTH) Chart for Sunday, February, 19, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Bio-Path Holdings (NASDAQ:BPTH)

Earnings History Chart

Earnings by Quarter for Bio-Path Holdings (NASDAQ:BPTH)

Dividend History Chart

Dividend Payments by Quarter for Bio-Path Holdings (NASDAQ:BPTH)

Last Updated on 2/19/2017 by MarketBeat.com Staff